Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).

Cortes, J., Kim, D., Pinilla Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., et al. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. NEW ENGLAND JOURNAL OF MEDICINE, 369(19), 1783-1796 [10.1056/NEJMoa1306494].

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

GAMBACORTI PASSERINI, CARLO;
2013-11-07

Abstract

Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).
Articolo in rivista - Articolo scientifico
Scientifica
Young Adult; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Humans; Aged; Protein Kinase Inhibitors; Thrombosis; Imidazoles; Thrombocytopenia; Pyridazines; Aged, 80 and over; Adult; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Adolescent; Female; Male
English
Cortes, J., Kim, D., Pinilla Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., et al. (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. NEW ENGLAND JOURNAL OF MEDICINE, 369(19), 1783-1796 [10.1056/NEJMoa1306494].
Cortes, J; Kim, D; Pinilla Ibarz, J; le Coutre, P; Paquette, R; Chuah, C; Nicolini, F; Apperley, J; Khoury, H; Talpaz, M; Dipersio, J; Deangelo, D; Abruzzese, E; Rea, D; Baccarani, M; Müller, M; GAMBACORTI PASSERINI, C; Wong, S; Lustgarten, S; Rivera, V; Clackson, T; Turner, C; Haluska, F; Guilhot, F; Deininger, M; Hochhaus, A; Hughes, T; Goldman, J; Shah, N; Kantarjian, H
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/52070
Citazioni
  • Scopus 762
  • ???jsp.display-item.citation.isi??? 678
Social impact